Form 4: HeartSciences Director David Wells Granted 25,000 Stock Options Under 2023 Equity Plan

HeartSciences Inc. Director David R. Wells was granted 25,000 stock options with an exercise price of $4.37, vesting over time, as part of the company's 2023 Equity Incentive Plan.

Summary

• David R. Wells, a Director of HeartSciences Inc. (HSCS), was granted 25,000 stock options.
• The options have an exercise price of $4.37 per share.
• The grant was effective July 9, 2025, and was approved by the compensation committee of the Issuer's board of directors.
• One-fourth of the options vested on July 9, 2025, with the remaining options scheduled to vest in equal increments every three months thereafter.
• Vesting is subject to Mr. Wells' continued service on the Board through each applicable vesting date.
• The options expire on July 9, 2035, which is ten years from the effective date.
• The grant was made pursuant to the Issuer's 2023 Equity Incentive Plan, as amended.

Sentiment

Score: 7

Explanation: The document reports a routine insider transaction involving the grant of stock options to a director. This is a standard compensation practice aimed at aligning interests, which is generally viewed as a neutral to slightly positive corporate governance action, indicating stability in compensation practices.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term value creation.
• The vesting schedule promotes the director's continued service and commitment to the company's strategic objectives.

Risks

• The vesting of the options is contingent upon the Reporting Person's continued service on the Board through each applicable vesting date.
• The options may terminate sooner than their stated expiration date of July 9, 2035, in accordance with the Issuer's 2023 Equity Incentive Plan or the underlying options grant agreement.

Future Outlook

The vesting schedule of the stock options implies an expectation of continued service from Director David R. Wells on the Board of HeartSciences Inc. for the options to fully vest over time.

Management Comments

• The compensation committee of the Issuer's board of directors approved the grant of these options to the Reporting Person.

Industry Context

Granting stock options to directors is a common practice across various industries, particularly in technology and healthcare, serving as a key component of executive compensation to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of 25,000 stock options to a director is a standard form of equity compensation, comparable to practices at similar-sized companies in the medical technology or diagnostics sector.
• The ten-year expiration period for the options is typical for such grants, providing a long-term incentive horizon.

Corporate Governance

Related Party Transactions

• The grant of 25,000 stock options to David R. Wells, a Director of HeartSciences Inc., constitutes a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value, potentially leading to improved company performance.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• David R. Wells' continued service on the Board is required for the remaining options to vest.
• Future vesting increments will occur every three months from July 9, 2025.

Key Dates

Keywords

HeartSciences, HSCS, Stock Options, Equity Incentive Plan, Director Compensation, SEC Form 4, Insider Transaction, David R. Wells